Materiały źródłowe

• #1 Synovial sarcoma – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/synovial-sarcoma/diagnosis-treatment/drc-20577401

  Treatment options for synovial sarcoma include: […] Surgery is the main treatment for synovial sarcoma. The goal is to remove the cancer and some of the healthy tissue around it. This can sometimes mean the removal of an entire muscle or muscle group. […] To lower the chances of the cancer returning, radiation therapy or chemotherapy might be used as well. […] Radiation therapy treats cancer with powerful energy beams. […] Radiation before surgery can shrink the cancer and make a successful surgery more likely. Radiation therapy after surgery can kill cancer cells that might still be there. […] Chemotherapy treats cancer with strong medicines. For synovial sarcoma, chemotherapy might be used before or after surgery. It also may be used when cancer has spread to other parts of the body.

• #1 Synovial sarcoma – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/synovial-sarcoma/diagnosis-treatment/drc-20577401

  Targeted therapy uses medicines that attack specific chemicals in the cancer cells. This can cause cancer cells to die or stop growing. Targeted therapy medicines are being studied for advanced synovial sarcoma. […] Cell therapy helps the immune system find and stop the cancer cells. This treatment involves taking some of your immune system cells and making them better at recognizing the cancer cells. […] One cell therapy used for synovial sarcoma is afamitresgene autoleucel (Tecelra). It might be an option for treating advanced synovial sarcoma that hasn’t been helped by chemotherapy. […] Clinical trials are studies of new treatments. These studies provide a chance to try the latest treatment options. The side effects may not be known. Ask your healthcare team if there is a clinical trial available to take part in.

• #2 Synovial Sarcoma: Symptoms, Treatment & Prognosis

  https://my.clevelandclinic.org/health/diseases/22012-synovial-sarcoma

  Surgery is the standard treatment for synovial sarcoma. The goal is to remove the tumor and some of the tissue around it to make sure it all comes out. In some cases, this means removing an entire muscle or muscle group. It depends on how far the cancer has spread. Your provider can tell you what to expect in your situation. […] Providers may do surgery as a stand-alone treatment or in combination with other therapies like: […] Healthcare providers base treatment on several factors like tumor size and location, how long you’ve had the tumor and whether the cancer has spread (metastasized). […] You can lower your risk of metastasis (Stage 4 synovial sarcoma) with early detection and treatment. Stay aware of changes in your body. Tell a healthcare provider if you develop a lump that causes pain or doesn’t go away in a couple of weeks.

• #2 Synovial Sarcoma: Symptoms, Treatment & Prognosis

  https://my.clevelandclinic.org/health/diseases/22012-synovial-sarcoma

  Healthcare providers have made huge strides in treating synovial cell sarcoma. But there’s still a chance the condition will recur (return), sometimes, many years after treatment. You’ll likely have checkups for several years so your providers can monitor you closely. […] The five-year survival rate for synovial sarcoma is 50% to 60%. That means that 5 to 6 out of 10 people with synovial sarcoma are still alive five years after their diagnosis. […] Survival rates are only estimates and depend on several factors. Researchers base them on previous outcomes for other people diagnosed with the same condition. Survival rates can’t tell you how long you’ll live or how you’ll respond to a specific treatment. To learn more about survival rates or to find out what they mean for your situation talk to your healthcare provider.

• #3 Treatment of Soft Tissue Sarcomas, by Stage | American Cancer Society

  https://www.cancer.org/cancer/types/soft-tissue-sarcoma/treating/by-stage.html

  The best chance to cure a soft tissue sarcoma is to remove it with surgery, so surgery is part of the treatment for all soft tissue sarcomas whenever possible. […] Studies have shown that people with sarcomas tend to have better outcomes when they’re treated at specialized cancer centers that have experience in sarcoma treatment. […] But in recent years, as doctors have learned more about the differences between the types, newer targeted therapy and immunotherapy drugs have become important treatment options for some types of advanced soft tissue sarcomas. […] The goal of surgery is to remove the tumor with some of the normal tissue around it. […] Another option is treating with radiation therapy after surgery. This lowers the chance of the cancer coming back. […] For these tumors, radiation with or without chemotherapy (chemo) may be given before surgery. This may shrink the tumor enough to remove it entirely with surgery.

• #4 Synovial Cell Sarcoma – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK587366/

  Treating patients with locally advanced unresectable or metastatic synovial sarcoma aims at palliation and prolonging life. The therapy involves using cytotoxic chemotherapy, tyrosine kinase inhibitors, or enrolling the patient in a clinical trial. […] Limb-sparing surgery is the mainstay of treatment for patients with synovial sarcoma who present with localized disease. Amputation is rarely pursued and reserved for patients where limb salvage is impossible. The goal is to achieve an R0 margin of at least 1 to 2 cm in width. […] In patients with localized synovial sarcoma, radiation therapy (RT) is used either in the preoperative or postoperative setting. In patients with metastatic or those with locally advanced, unresectable tumors, RT can be given for palliative purposes (pain relief, cord compression).

• #4 Synovial Cell Sarcoma – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK587366/

  Synovial sarcoma is defined by the translocation between chromosome X and 18, which leads to the expression of SS18:SSX fusion proteins. […] This activity reviews the presentation, diagnosis, treatment, and role of interprofessional teams in managing patients diagnosed with synovial sarcoma. […] Review the treatment options available for synovial sarcoma. […] Surgical resection (to achieve microscopic negative margins) along with perioperative radiotherapy remains the cornerstone of treatment. […] The role of neoadjuvant or adjuvant chemotherapy remains controversial in adults but is utilized regularly in the pediatric population. […] The treatment of patients with synovial sarcoma is based on the stage of presentation. A patient with SS can either present with localized or metastatic disease. Generally, a localized disease is approached to achieve a microscopic negative margin (R0 resection) surgically. Where neoadjuvant chemotherapy is widely used in the pediatric population, the use of neoadjuvant chemotherapy is controversial in adults.

• #4 Synovial Cell Sarcoma – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK587366/

  The medical oncologist ensures that a proper regimen gets chosen according to the presentation of the patient. The drugs involved in treating synovial sarcoma include a host of cytotoxic and targeted agents that come with unique toxicities. […] Neoadjuvant or adjuvant chemotherapy affords better survival in children (based on non-randomized retrospective data) but remains controversial in adults. Hence, neoadjuvant or adjuvant chemotherapy is offered more commonly in the pediatric age group. […] Anthracycline-based regimens are the first choice in treating patients with SS in the neoadjuvant, adjuvant, or metastatic setting.

• #5 Synovial Sarcoma Treatment & Management: Approach Considerations, Chemotherapy, Surgical Therapy

  https://emedicine.medscape.com/article/1257131-treatment

  The efficacy of chemotherapy as adjuvant treatment after surgery has been a controversial aspect of treatment of synovial sarcoma. Chemotherapy has not proved to provide a significant benefit in survival rates in all series. […] However, a retrospective analysis of 271 patients with synovial sarcoma, of whom 41% received adjuvant chemotherapy, found that the 5-year metastasis-free survival (MFS) rate was 60% for those who were treated with chemotherapy and 48% for those who were not. […] Surgical excision is still the cornerstone of treatment for synovial sarcoma. A tumor-free margin of 1-3 cm is recommended. […] Maximal care must be taken to reduce the risk of local recurrence. Careful preoperative planning is essential. […] Preoperative radiation therapy (RT) is associated with an increased rate of wound problems. This neoadjuvant RT is sometimes proposed before surgery to reduce the size of the tumor.

• #5 Synovial Sarcoma Treatment & Management: Approach Considerations, Chemotherapy, Surgical Therapy

  https://emedicine.medscape.com/article/1257131-treatment

  There are no contraindications for surgical treatment of synovial sarcoma (also referred to as synovial cell sarcoma), which is potentially life-saving. There is a relative contraindication for treating these patients in primary centers. Early referral to tertiary centers for definitive treatment must be preferred. Ideally, treatment should be performed by a multidisciplinary team with personnel experienced in the management of soft-tissue sarcomas. […] Adjuvant chemotherapy and neoadjuvant chemotherapy have been proposed for patients with metastatic soft-tissue sarcomas. Although chemotherapy in the treatment of synovial sarcoma has been controversial, some studies have shown overall survival benefits in selected patients. […] Ladenstein et al reported improved survival rates with the use of adjuvant doxorubicin- and cyclophosphamide-based chemotherapy.

• #5 Synovial Sarcoma Treatment & Management: Approach Considerations, Chemotherapy, Surgical Therapy

  https://emedicine.medscape.com/article/1257131-treatment

  RT is usually required in addition to surgery, particularly if the margins are close to vital neurovascular structures. The most common form of RT in this setting is external-beam RT (EBRT) that is directed at the tumor site and that includes a margin of surrounding normal tissue. […] The local radiation dose is usually 40-60 Gy. Proximity of vital neurologic structures, open physes, or an extreme peripheral location (hand or foot) can make EBRT potentially hazardous. […] The surgical complications are related to the site involved but include the general complications of wound infection, wound breakdown, neurologic or vascular injury, and hematoma or seroma formation. […] Follow-up involves clinical examination, MRI of the surgical site, and CT of the chest. After surgical treatment, the authors recommend MRI, CT, and a patient review every 3-6 months for the first 2 years and then every 6 months for the next 3 years.

• #6 Synovial sarcoma: the misdiagnosed sarcoma in: EFORT Open Reviews Volume 9 Issue 3 (2024)

  https://eor.bioscientifica.com/view/journals/eor/9/3/EOR-23-0193.xml

  Surgery is the mainstay of treatment for synovial sarcomas. Neoadjuvant/adjuvant radiotherapy is recommended for patients with big tumors (5 cm) or positive resection margins, and neoadjuvant/adjuvant chemotherapy is recommended for patients with high-risk tumors or advanced diseases. […] Neoadjuvant/adjuvant radiotherapy has shown to improve local control and may have an overall survival (OS) benefit in patients with SS. […] Since early studies confirmed that neoadjuvant chemotherapy based on ifosfamide had an impressive response to treatment of metastatic and pediatric SS, SS was considered to be a particularly chemosensitive STS. […] In general, chemotherapy is reserved for patients with high-risk tumors or advanced diseases and is considered to be more effective in younger patients.

• #6 Synovial sarcoma: the misdiagnosed sarcoma in: EFORT Open Reviews Volume 9 Issue 3 (2024)

  https://eor.bioscientifica.com/view/journals/eor/9/3/EOR-23-0193.xml

  The EMSO guidelines recommend chemotherapy as an option for limb-preserving surgery, and recommend at least three cycles of adjuvant or neoadjuvant chemotherapy for patients at a high risk of death. […] In the field of research on targeted therapies for SS, new agents including receptor tyrosine kinase inhibitors, epigenetic modifiers, and immunotherapies have been investigated in clinical trials. However, only pazopanib, a receptor tyrosine kinase inhibitor, is approved for clinical use.

• #7 Adjuvant radiotherapy for synovial sarcoma of the hand: a case report and literature review – Wang – Therapeutic Radiology and Oncology

  https://tro.amegroups.org/article/view/4517/html

  As postoperative radiation therapy for synovial sarcoma, a 22-year-old male patient was treated with a total dose of 60 Gy, administered in 30 daily fractions. […] Adjuvant radiation therapy is employed in synovial sarcoma under the same rationale as it is employed in soft tissue sarcomas. […] Adjuvant radiation therapy modalities include brachytherapy, conventional two-dimensional radiotherapy, and intensity-modulated radiation therapy. […] The local control rate in patients with high-grade sarcomas such as synovial sarcoma has been demonstrated to be higher when radiation therapy is employed, irrespective of the radiation therapy type. […] In one study, 61.2 Gy (range, 45-66.6 Gy) was discovered to be a sufficient dose in adjuvant radiotherapy, with 5-year overall survival being 77% and 10-year overall survival being 65%.

• #8

  https://link.springer.com/article/10.1007/s11864-018-0525-1

  Synovial sarcoma (SS) is a rare, yet highly malignant, type of soft tissue sarcoma (STS), for which survival has not improved significantly during the past years. In this review, we focus on systemic treatment in adults. Compared to other STS, SS are relatively chemosensitive. Ifosfamide and ifosfamide combinations are active in different lines of treatment. In high-risk extremity and chest wall STS, neoadjuvant doxorubicin and ifosfamide has shown as much activity as high-dose ifosfamide. There are indications that combination chemotherapy with doxorubicin and ifosfamide in this setting improves outcome. In the first-line metastatic setting, combination treatment with doxorubicin and ifosfamide is a preferred option in fit patients, while in other patients, sequential doxorubicin and ifosfamide can be considered. In second and later lines, pazopanib and trabectedin have shown activity. Many new approaches to treat metastatic SS are currently under investigation, both preclinical as well as clinical, including other receptor tyrosine kinase inhibitors, epigenetic modulators, compounds interfering with DNA damage response (DDR), and immunotherapy.

• #8

  https://link.springer.com/article/10.1007/s11864-018-0525-1

  For localized non high-risk disease, treatment consists of surgery, on indication combined with (neo)adjuvant radiotherapy. In about 50% of cases, metastases occur. […] Once metastasized, curative treatment is hardly achievable, with the exception of late and resectable oligometastatic disease and patients are treated with chemotherapy with a palliative intent. Compared to STS as a group, SS is more sensitive to certain chemotherapeutic agents. […] In conclusion, in fit patients, data suggest that SS patients might benefit from first-line combination treatment of ifosfamide with doxorubicin over monotherapy doxorubicin, although due to the rarity of the disease this conclusion is not based on a prospective randomized study in SS. […] For SS, the second-line treatment of first choice for the majority of fit patients is ifosfamide, based on its known activity in SS. Alternative options are pazopanib and trabectedin in case patients are not fit enough for ifosfamide or have received the combination of doxorubicin and ifosfamide in first line.

• #8

  https://link.springer.com/article/10.1007/s11864-018-0525-1

  At present, however, pazopanib is still the only targeted drug approved for the treatment of STS, including SS, in the advanced setting after failure of standard cytotoxic therapy. […] In conclusion, although it is too early to conclude on the efficacy of immunotherapy in SS, therapy based on engineered T cells showed exciting early results.

• #9 Efficacy of perioperative chemotherapy for synovial sarcoma: a retrospective analysis of a Nationwide database in Japan | BMC Cancer | Full Text

  https://bmccancer.biomedcentral.com/articles/10.1186/s12885-021-08485-1

  Synovial sarcoma is an aggressive but chemosensitive soft-tissue tumor. […] The administration of perioperative chemotherapy might be a rational approach to reduce micro-invasion from the primary site. […] However, chemotherapy for SS remains controversial because it is difficult to conduct a prospective study on the efficacy of perioperative therapy, specifically for this tumor type. […] This large-sample study indicated that the margin status and postoperative disease control were associated directly or indirectly with improved oncologic outcomes. However, the efficacy of perioperative chemotherapy for survival outcomes in synovial sarcoma patients was not proven in this Japanese database analysis. […] In the cx+group, most patients underwent perioperative chemotherapy with either the adriamycin + ifosfamide (AI) regimen or another doxorubicin regimen, administered along with cisplatin, ifosfamide, dacarbazine, or vincristine.

• #10 Relapsed synovial sarcoma | CMAR

  https://www.dovepress.com/treatment-at-relapse-for-synovial-sarcoma-of-children-adolescents-and–peer-reviewed-fulltext-article-CMAR

  In case of metastatic relapse, systemic therapy used in neo-adjuvant setting should have a major role, with local treatment in case of concomitant local relapse and treatment on metastases (surgery/radiotherapy/thermal ablation) depending on site, number and size of metastatic lesions. […] The ifosfamide-doxorubicin chemotherapy (currently considered the standard front-line chemotherapy in SS) should certainly be considered the best option for relapsed patients that did not previously receive this combination upfront. […] Other chemotherapy options that showed some activity in patients with relapsed SS (in limited retrospective experiences) are: […] High-dose ifosfamide. […] Trabectedin. […] In a relapse setting, the combination of the monoclonal anti-vascular endothelial growth factor (VEGF) antibody ramucirumab with gemcitabine/docetaxel has been tested in patients with relapsed/refractory SS (NCT04145700), but results are not yet available.

• #10 Relapsed synovial sarcoma | CMAR

  https://www.dovepress.com/treatment-at-relapse-for-synovial-sarcoma-of-children-adolescents-and–peer-reviewed-fulltext-article-CMAR

  In fact, in the subset of patients without any risk factor (only 7 out of 41 cases analysed for this purpose), 5-year OS was 85.7%; when at least one factor was present (early relapse or metastatic, secondary remission not reached), 5-year OS drastically decreased to 18.7%. […] There is no uniform standardised approach to treat young patients with relapsed SS. Multimodal treatment has to be tailored to each patient depending on their previous upfront treatment, type of recurrence, time to relapse and patients/parents opinion. […] In general, there is a consensus that patients with exclusive local relapse should promptly receive microscopically complete tumour resection, whenever possible. […] Local treatments (surgery and radiotherapy) remain a key stone of the therapeutic approach. Systemic treatment should be considered, however, and probably used in all cases, in neo-adjuvant and/or adjuvant setting.

• #11 Targeted therapy for soft tissue sarcoma | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/soft-tissue-sarcoma/treatment/targeted-therapy

  Pazopanib (Votrient) is a TKI drug that may be used to treat soft tissue sarcoma. It targets many different proteins including VEGF (vascular endothelial growth factor), which helps cells form new blood vessels. Pazopanib works by finding and attaching to VEGF and preventing cells from forming new blood vessels that they need to grow. […] Pazopanib may be used for some types of advanced soft tissue sarcoma when chemotherapy has already been given or the soft tissue sarcoma has continued to grow within 1 year after treatment. It is taken as a pill once a day. […] Imatinib (Gleevec) is another TKI that may also be used to treat soft tissue sarcoma. It targets many different proteins including the KIT protein, which helps cells grow, divide and move around. […] Imatinib may be used for:

• #12 Soft Tissue Sarcoma Treatment – NCI

  https://www.cancer.gov/types/soft-tissue-sarcoma/patient/adult-soft-tissue-treatment-pdq

  Immunotherapy is a treatment that uses the patient’s immune system to fight cancer. […] Treatment for soft tissue sarcoma may cause side effects. […] Patients may want to think about taking part in a clinical trial. […] Treatment of stage I soft tissue sarcoma may include the following: Surgery to remove the tumor, such as Mohs microsurgery for small sarcomas of the skin, wide local excision, or limb-sparing surgery. […] Treatment of stage II soft tissue sarcoma and stage III soft tissue sarcoma that has not spread to lymph nodes may include the following: Surgery to remove the tumor, such as wide local excision or limb-sparing surgery. […] Treatment of stage III soft tissue sarcoma that has spread to lymph nodes (advanced) may include the following: Surgery (wide local excision) with lymphadenectomy.

• #13 Genetic and Molecular Heterogeneity of Synovial Sarcoma and Associated Challenges in Therapy

  https://www.mdpi.com/2073-4409/13/20/1695

  Synovial sarcoma (SS) is one of the most common types of pediatric soft tissue sarcoma (STS) being far less frequent in adults. Currently, targeted therapy for synovial sarcoma includes a limited range of drugs, and surgical resection is the mainstay treatment for localized cancer with adjuvant or neoadjuvant chemotherapy and radiotherapy. […] Understanding the molecular characteristics of synovial sarcoma subtypes is becoming increasingly important for detecting new potential targets and developing innovative therapies. Novel approaches to treating synovial sarcoma include immune-based therapies (such as TCR-T cell therapy to NY-ESO-1, MAGE4, PRAME or using immune checkpoint inhibitors), epigenetic modifiers (HDAC inhibitors, EZH2 inhibitors, BRD disruptors), as well as novel or repurposed receptor tyrosine kinase inhibitors.

• #13 Genetic and Molecular Heterogeneity of Synovial Sarcoma and Associated Challenges in Therapy

  https://www.mdpi.com/2073-4409/13/20/1695

  Despite significant advances in the molecular studies of the pathogenesis and progression of SS, surgery combined with neoadjuvant or adjuvant therapies (radiotherapy and chemotherapy) is the standard of care for this cancer type. The front-line therapy (anthracyclines and ifosfamide) is followed by the not-so-well-established second line of the minor groove binder trabectedin and receptor tyrosine kinase inhibitors such as pazopanib, sorafenib, and the monoclonal anti-VEGF antibody bevacizumab. […] Innovative approaches include immune-based therapies (NY-ESO-1, MAGE4, PRAME), HDAC inhibitors, BRD disruptors and modifiers of developmental pathways (Notch, Hedgehog, and Wnt/β-catenin pathways).

• #14 FDA Approves First Gene Therapy to Treat Adults with Metastatic Synovial Sarcoma | FDA

  https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treat-adults-metastatic-synovial-sarcoma

  The U.S. Food and Drug Administration approved Tecelra (afamitresgene autoleucel), a gene therapy indicated for the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA antigen(s) A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive, and whose tumor expresses the MAGE-A4 antigen as determined by FDA authorized companion diagnostic devices. […] Treatment typically involves surgery to remove the tumor and may also include radiotherapy and/or chemotherapy if the tumor is larger, returns after being removed or has spread beyond its original location. […] Tecelra is also the first FDA-approved T cell receptor (TCR) gene therapy. […] Tecelra was approved using the Accelerated Approval pathway, under which the FDA may approve drugs for serious or life-threatening diseases or conditions where there is an unmet medical need and the drug is shown to have an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients (improving how patients feel or function, or whether they survive longer).

• #14 FDA Approves First Gene Therapy to Treat Adults with Metastatic Synovial Sarcoma | FDA

  https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treat-adults-metastatic-synovial-sarcoma

  Adults with metastatic synovial sarcoma, a life-threatening form of cancer, often face limited treatment options in addition to the risk of cancer spread or recurrence, said Nicole Verdun, M.D., director of the Office of Therapeutic Products in CBER. […] The safety and effectiveness of Tecelra was evaluated in a multicenter, open-label clinical trial including patients with inoperable and metastatic synovial sarcoma who had received prior systemic therapy and whose tumor expressed the MAGE-A4 tumor antigen. Effectiveness was evaluated based on overall response rate and the duration of response to treatment with Tecelra. Among the 44 patients in the trial who received Tecelra, the overall response rate was 43.2% and the median duration of response was six months.

• #15 Treatment of Soft Tissue Sarcomas, by Stage | American Cancer Society

  https://www.cancer.org/cancer/types/soft-tissue-sarcoma/treating/by-stage.html

  Radiation may be given after surgery. […] The goal of treatment is to shrink the tumor, making it easier to remove. […] Chemo, radiation, or both might also be given after surgery. These treatments lower the chance of the tumor coming back in or near the same place it started. […] Radiation therapy with or without chemo can be used alone when the tumor’s location or size or the patient’s overall health makes surgery impossible. […] The best success rate is when it has spread only to the lungs. […] For people whose primary tumor and all metastases cannot be removed completely by surgery, radiation therapy and/or chemotherapy are often used. […] For some types of soft tissue sarcomas, treatment with newer targeted drugs or immunotherapy might also be an option. […] If the sarcoma comes back in the same area where it started, it may be treated with surgery. […] If the sarcoma returns in a distant part of the body, chemo, targeted therapy, or immunotherapy drugs may be options.

• #15 Treatment of Soft Tissue Sarcomas, by Stage | American Cancer Society

  https://www.cancer.org/cancer/types/soft-tissue-sarcoma/treating/by-stage.html

  The best chance to cure a soft tissue sarcoma is to remove it with surgery, so surgery is part of the treatment for all soft tissue sarcomas whenever possible. […] Studies have shown that people with sarcomas tend to have better outcomes when they’re treated at specialized cancer centers that have experience in sarcoma treatment. […] But in recent years, as doctors have learned more about the differences between the types, newer targeted therapy and immunotherapy drugs have become important treatment options for some types of advanced soft tissue sarcomas. […] The goal of surgery is to remove the tumor with some of the normal tissue around it. […] Another option is treating with radiation therapy after surgery. This lowers the chance of the cancer coming back. […] For these tumors, radiation with or without chemotherapy (chemo) may be given before surgery. This may shrink the tumor enough to remove it entirely with surgery.

• #16 Synovial sarcoma – Wikipedia

  https://en.wikipedia.org/wiki/Synovial_sarcoma

  Treatment is usually multimodal, involving surgery, chemotherapy and radiotherapy: […] Surgery, to remove the tumor and a safety margin of healthy tissue. This is the mainstay of synovial sarcoma treatment and is curative in approximately 20-70% of patients, depending on the particular study being quoted. […] Conventional chemotherapy, (for example, doxorubicin hydrochloride and ifosfamide), to reduce the number of remaining microscopic metastases. The benefit of chemotherapy in synovial sarcoma to overall survival remains unclear, although a recent study has shown that survival of patients with advanced, poorly differentiated disease marginally improves with doxorubicin/ifosfamide treatment. […] Radiotherapy to reduce the chance of local recurrence. The benefit of radiotherapy in this disease is less clear than for chemotherapy. […] Afamitresgene autoleucel (Tecelra) was approved for medical use in the United States in August 2024.

• #17 Treatments for soft tissue sarcoma | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/soft-tissue-sarcoma/treatment

  If you have soft tissue sarcoma, your healthcare team will create a treatment plan just for you. It will be based on your health and specific information about the cancer. When deciding which treatments to offer for soft tissue sarcoma, your healthcare team will consider: […] The care and treatment of people with soft tissue sarcoma is often done by a healthcare team that is experienced in dealing with soft tissue sarcoma. Most cases of soft tissue sarcoma need to be managed by many specialists, including a radiologist, surgeon, medical oncologist and radiation oncologist. […] Surgery is usually the primary treatment for stage 1 soft tissue sarcoma. […] Surgery is usually the primary treatment for stage 2 and 3 soft tissue sarcomas. […] Stage 4 soft tissue sarcoma can be treated with a combination of therapies, including chemotherapy, radiation and surgery.

• #18 Investigational drug attacks synovial sarcoma, a rare type of tumor – WashU Medicine

  https://medicine.washu.edu/news/investigational-drug-attacks-synovial-sarcoma-a-rare-type-of-tumor/

  A new study from Washington University School of Medicine in St. Louis describes a potential new therapy for synovial sarcoma, a rare tumor of soft tissues. […] Researchers at Washington University School of Medicine in St. Louis have developed a way to attack synovial sarcoma a rare tumor of soft tissues, such as ligaments and muscles using an investigational drug that triggers cell death. […] The drug was developed by Washington University researchers who are planning a phase 1 clinical trial to investigate its safety and effectiveness in patients who have synovial sarcoma that has spread beyond the original tumor site. […] If its diagnosed early, this cancer can be cured with standard care surgery, radiation and chemotherapy. But once it spreads, we have no effective curative therapies, so were looking for new treatment strategies that take advantage of the genetic quirks of this rare tumor.

• #18 Investigational drug attacks synovial sarcoma, a rare type of tumor – WashU Medicine

  https://medicine.washu.edu/news/investigational-drug-attacks-synovial-sarcoma-a-rare-type-of-tumor/

  The investigational drug ACXT-3102 interferes with this alternate route. […] The drug ACXT-3102 was developed by William G. Hawkins, MD, the Neidorff Family and Robert C. Packman Professor of Surgery, and his team, to treat pancreatic cancer. […] The researchers suspect that this rare tumor could be treatable with ACXT-3102 alone. […] Finding a weakness in cancer that we can exploit based on the biology of a rare tumor is really exciting. […] The drug ACXT-3102 was licensed to a Washington University startup company called Accuronix Therapeutics that was co-founded by Hawkins to develop new cancer therapies.

• #19 Synovial Sarcoma Treatment Breakthrough | FOMAT Medical

  https://www.fomatmedical.com/news-posts/potential-treatment-for-childhood-sarcoma-cancer/

  Significantly, they found a protein (BRD9) that is essential for the survival of synovial sarcoma cells. […] Next, using cutting-edge approaches to drug design, they created a new BRD9 degrader drug, and in pre-clinical trials in mice, they found that BRD9 degradation was successful in blocking the progression of synovial sarcoma tumors. […] Excitingly, our work demonstrates that degrading BRD9 impedes the SS18-SSX protein, which is the underlying cause of synovial sarcoma. […] We now hope these promising findings will lead to clinical trials of this new drug in patients in the near future.

Zobacz więcej